Joaquín Fra

Suggest Changes
Learn More
PURPOSE To assess the activity and toxicity of the combination of gemcitabine plus dacarbazine (DTIC) in patients with advanced soft tissue sarcoma (STS) in a randomized, multicenter, phase II study(More)
Topotecan, a semi-synthetic camptothecin analogue with topoisomerase I interaction, has shown to be an active agent in the treatment of advanced refractory lung cancer. This paper describes the(More)
INTRODUCTION For nearly the past two decades, cytokines (CKs) have been the only systemic treatment option available for advanced renal cell carcinoma (RCC). In recent years, tyrosine kinase(More)
BACKGROUND Docetaxel and paclitaxel have activity in the second-line treatment of non-small-cell lung cancer (NSCLC), and can be administered as weekly schedules. This phase II randomised study was(More)
10529 Background: Dacarbazine (D) and gemcitabine (G) are active as single agents in the treatment of patients (pts) with advanced soft tissue sarcoma (STS) resistant to standard chemotherapy. The(More)
PURPOSE To assess the progression-free survival (PFS) and antitumor response to standard-dose doxorubicin compared with sequential dose-dense doxorubicin and ifosfamide in first-line treatment of(More)